EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyseOpen Access · CC BY 4.0

The Effects of Glucagon‐Like Peptide‐1 Receptor Agonists and Sodium‐Glucose Co‐Transporter‐2 Inhibitors on Lean Body Mass in Humans: A Systematic Review and Meta‐Analysis of Randomised Controlled Trials

Rishi Jobanputra iD, Jack A Sargeant, Tatiana Plekhanova, Emily James iD, Abdullah Almaqhawi iD, David R Webb, Melanie J Davies, Thomas Yates

Diabetes/Metabolism Research and Reviews · 2026-07 · 42 (5)

DOI: 10.1002/dmrr.70194 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Diabetes/Metabolism Research and Reviews, online erschienen am 19.06.2026. Verfasst von Rishi Jobanputra und 7 weiteren Autor:innen. Beteiligte Einrichtung: Diabetes Research Centre, University of Leicester, Leicester, UK. Hauptthemen laut MEDLINE: Body Composition, Diabetes Mellitus, Type 2, Glucagon-Like Peptide-1 Receptor Agonists, Hypoglycemic Agents. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 78 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Institute for Health Research, Leicester Biomedical Research Centre, the NIHR Leicester Clinical Research Facility.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

The use of pharmacotherapies with weight loss properties for the management of obesity and chronic disease are now routinely prescribed. We investigated the evidence from randomised‐controlled trials for the effects on lean body mass of glucagon‐like peptide‐1 receptor agonists (GLP‐1RA) and sodium‐glucose co‐transporter‐2 inhibitors (SGLT2i) in humans. Materials and Methods PubMed, MEDLINE, the Cochrane Library and CINAHL were searched from inception to October 2022. The primary outcome was change in body composition focused on measures of lean body mass (LBM).

Results

Thirty‐six studies in population groups with obesity ( n = 8), type 2 diabetes mellitus ( n = 20), type 1 diabetes mellitus ( n = 5) and polycystic ovary syndrome ( n = 3) receiving a GLP‐1RA or SGLT2i therapy versus placebo or active comparator satisfied our inclusion criteria, including 21 for GLP‐1RA and 15 for SGLT2i. Meta‐analysis showed an overall loss of LBM in the direction of the intervention groups prescribed GLP‐1RA (MD: −1.51 kg [95% CI: −2.00 to −1.01]) and SGLT2i (MD: −1.04 kg [95% CI: −1.45 to −0.64]) with sub‐group analysis showing largely consistent results when stratified by type of body composition outcome, type of body composition measurement technique and disease status. Results were not modified by sex. Further meta‐analysis found that lean mass accounted for 28% (95% CI: 22%–34%) of overall weight loss induced by GLP‐1RA and SGLT2i.

Conclusions

GLP‐1RA and SGLT2i are associated with a loss of LBM that appears congruent with overall weight loss. Monitoring of body composition and provision of combined therapy to preserve lean mass during weight loss should be considered.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Body CompositionDiabetes Mellitus, Type 2Glucagon-Like Peptide-1 Receptor AgonistsHypoglycemic AgentsObesitySodium-Glucose Transporter 2 InhibitorsFemaleHumansPolycystic Ovary SyndromeRandomized Controlled Trials as TopicWeight Loss

Stichwörter der Autor:innen

body compositionglucagon‐like peptide‐1 receptor agonistslean body masssodium‐glucose co‐transporter‐2 inhibitorsweight loss

Substanzen

Glucagon-Like Peptide-1 Receptor AgonistsHypoglycemic AgentsSodium-Glucose Transporter 2 Inhibitors

Autor:innen und Institutionen

  • Diabetes Research Centre, University of Leicester, Leicester, UK.
  • National Institute for Health Research (NIHR) Leicester Biomedical Research Centre, Leicester, UK.
  • Department of Family and Community Medicine, College of Medicine, King Faisal University, Al Ahsa, Saudi Arabia.

ORCID-Profile: Rishi Jobanputra, Emily James, Abdullah Almaqhawi

Förderung

  • National Institute for Health Research
  • Leicester Biomedical Research Centre
  • the NIHR Leicester Clinical Research Facility
  • the NIHR Applied Research Collaboration East Midlands

Zitieren

APA

Jobanputra, R., Sargeant, J. A., Plekhanova, T., James, E., Almaqhawi, A., Webb, D. R., Davies, M. J., & Yates, T. (2026). The Effects of Glucagon‐Like Peptide‐1 Receptor Agonists and Sodium‐Glucose Co‐Transporter‐2 Inhibitors on Lean Body Mass in Humans: A Systematic Review and Meta‐Analysis of Randomised Controlled Trials. Diabetes/Metabolism Research and Reviews, 42(5). https://doi.org/10.1002/dmrr.70194

Vancouver

Jobanputra R, Sargeant JA, Plekhanova T, James E, Almaqhawi A, Webb DR, et al. The Effects of Glucagon‐Like Peptide‐1 Receptor Agonists and Sodium‐Glucose Co‐Transporter‐2 Inhibitors on Lean Body Mass in Humans: A Systematic Review and Meta‐Analysis of Randomised Controlled Trials. Diabetes/Metabolism Research and Reviews. 2026;42(5). doi:10.1002/dmrr.70194

BibTeX
@article{Jobanputra2026,
  author = {Jobanputra, Rishi and Sargeant, Jack A and Plekhanova, Tatiana and James, Emily and Almaqhawi, Abdullah and Webb, David R and Davies, Melanie J and Yates, Thomas},
  title = {The Effects of Glucagon‐Like Peptide‐1 Receptor Agonists and Sodium‐Glucose Co‐Transporter‐2 Inhibitors on Lean Body Mass in Humans: A Systematic Review and Meta‐Analysis of Randomised Controlled Trials},
  journal = {Diabetes/Metabolism Research and Reviews},
  year = {2026},
  volume = {42},
  number = {5},
  doi = {10.1002/dmrr.70194}
}
Kostenlos starten →